NASDAQ:IRD Opus Genetics (IRD) Stock Price, News & Analysis $5.22 +0.02 (+0.40%) As of 12:38 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Opus Genetics Stock (NASDAQ:IRD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Opus Genetics alerts:Sign Up Key Stats Today's Range$5.03▼$5.3250-Day Range$3.45▼$5.7552-Week Range$0.90▼$5.81Volume288,533 shsAverage Volume889,495 shsMarket Capitalization$372.78 millionP/E RatioN/ADividend YieldN/APrice Target$10.30Consensus RatingModerate Buy Company Overview Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan. Read More Opus Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreIRD MarketRank™: Opus Genetics scored higher than 70% of companies evaluated by MarketBeat, and ranked 196th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingOpus Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialOpus Genetics has a consensus price target of $10.30, representing about 98.1% upside from its current price of $5.20.Amount of Analyst CoverageOpus Genetics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Opus Genetics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Opus Genetics are expected to decrease in the coming year, from ($0.56) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Opus Genetics is -6.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Opus Genetics is -6.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOpus Genetics has a P/B Ratio of 23.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Opus Genetics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.88% of the float of Opus Genetics has been sold short.Short Interest Ratio / Days to CoverOpus Genetics has a short interest ratio ("days to cover") of 2.75, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Opus Genetics has recently decreased by 2.13%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOpus Genetics does not currently pay a dividend.Dividend GrowthOpus Genetics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.51 News SentimentOpus Genetics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Opus Genetics this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for IRD on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows2 people have added Opus Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Opus Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $382,278.00 in company stock.Percentage Held by Insiders11.70% of the stock of Opus Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions14.97% of the stock of Opus Genetics is held by institutions.Read more about Opus Genetics' insider trading history. Receive IRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opus Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRD Stock News HeadlinesHere is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ StocksMay 5 at 3:00 PM | insidermonkey.comOpus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) ProgramMay 4 at 4:30 PM | globenewswire.comSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses an emerging potential $10 trillion technology backed by Elon Musk and Sam Altman. This breakthrough could completely replace our need for foreign oil - and send one small group of stocks soaring in the process.May 6 at 1:00 AM | Altimetry (Ad)Piper Sandler Sticks to Its Buy Rating for Opus Genetics (IRD)May 2, 2026 | theglobeandmail.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Opus Genetics (IRD), NeoGenomics (NEO) and Teladoc (TDOC)May 2, 2026 | theglobeandmail.comCitizens Initiates Coverage of Opus Genetics (IRD)May 1, 2026 | insidermonkey.comCitizens Initiates Coverage of Opus Genetics (IRD) with Market Outperform RecommendationApril 29, 2026 | msn.comJoseph Schachle Sells 4,697 Shares of Opus Genetics (NASDAQ:IRD) StockApril 28, 2026 | insidertrades.comSee More Headlines IRD Stock Analysis - Frequently Asked Questions How have IRD shares performed this year? Opus Genetics' stock was trading at $2.01 on January 1st, 2026. Since then, IRD shares have increased by 158.7% and is now trading at $5.20. How were Opus Genetics' earnings last quarter? Opus Genetics, Inc. (NASDAQ:IRD) announced its quarterly earnings results on Wednesday, November, 12th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. The firm earned $3.08 million during the quarter, compared to analysts' expectations of $3.07 million. Opus Genetics had a negative trailing twelve-month return on equity of 338.88% and a negative net margin of 349.33%. Who are Opus Genetics' major shareholders? Top institutional investors of Opus Genetics include Regency Capital Management Inc. DE (0.10%) and Kestra Private Wealth Services LLC (0.02%). Insiders that own company stock include Fighting Blindness Foundation, Cam Gallagher, Cam Gallagher, George Magrath, Benjamin R Yerxa, Benjamin R Yerxa, Robert E Gagnon, Ashwath Jayagopal, Joseph K Schachle and Rabourn Amy Zaremba. View institutional ownership trends. How do I buy shares of Opus Genetics? Shares of IRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/12/2025Today5/06/2026Next Earnings (Estimated)5/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 IRD's financial health is in the Green zone, according to TradeSmith. IRD has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IRD Previous SymbolNASDAQ:IRD CIK1228627 Webwww.ocuphire.com Phone248-957-9024Fax240-268-5310Employees14Year Founded2018Price Target and Rating Average Price Target for Opus Genetics$10.30 High Price Target$15.00 Low Price Target$7.00 Potential Upside/Downside+97.3%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$49.59 million Net Margins-349.33% Pretax Margin-349.33% Return on Equity-338.88% Return on Assets-85.82% Debt Debt-to-Equity RatioN/A Current Ratio6.43 Quick Ratio6.43 Sales & Book Value Annual Sales$14.20 million Price / Sales26.25 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book23.73Miscellaneous Outstanding Shares71,400,000Free Float63,048,000Market Cap$372.78 million OptionableN/A Beta0.62 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:IRD) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersA U.S. Resource Gap Is a National Issue - and OpportunityAmerica still does not domestically produce one mineral tied to batteries, energy storage, and national defens...i2i Marketing Group, LLC | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredTrump and Elon are BACK15X Bigger Than SpaceX: Elon's New Launch While the rest of the market goes crazy for "the mother of all IP...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
